The invention discloses a
salvia miltiorrhiza acetyl-CoA acyltryansferase (SmAACT)
gene, prolease encoded by the
gene and application. The
gene is obtained by
cloning from
salvia miltiorrhiza by utilizing cDNA
chip technology for the first time, and therefore fills the gap of separating and
cloning an acetyl-CoA acyltryansferase gene from the
salvia miltiorrhiza, a traditional rare medicinal material in our country. The SmAACT gene has a
nucleotide sequence shown in SEQ IDNO.1 or a
homologous sequence which adds, substitutes, inserts or deletes one or more nucleotides or
nucleotide sequences of an
allelic gene and a derivative thereof.
Protein encoded by the gene has a
nucleotide sequence shown in SEQ ID No.2 or a
homologous sequence which adds, substitutes, inserts or deletes one or more nucleotides. The
salvia miltiorrhiza acetyl-CoA acyltryansferase catalyzes a first enzymatic reaction on an MVA pathway, ensures that acetyl-CoA with two molecules is condensed into acetyl acetyl-CoA, and is first key
enzyme on a biosynthetic pathway of diterpenoid tanshinone compounds from the
salvia miltiorrhiza; and the expression level of the gene is estimated to be closely related to the content of tanshinone components. The SmAACT gene can improve the content of
diterpene active components, namely tanshinones in the
salvia miltiorrhiza through
biotechnology, can be used for the research and industrialization on improving the content of tanshinone substances by utilizing the
biotechnology, is favorable for the quality improvement and breeding of salvia miltiorrhiza medicinal materials, and has good application prospect.